We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+4.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.07B
AUM Growth
+$160M
(+2%)
Cap. Flow
-$9.78B
Cap. Flow
% of AUM
-121.29%
Top 10 Holdings %
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$192M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$173M |
| 3 |
Merck
MRK
|
+$94.1M |
| 4 |
Tenet Healthcare
THC
|
+$83.4M |
| 5 |
DaVita
DVA
|
+$79.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$9.91B |
| 2 |
Eli Lilly
LLY
|
+$193M |
| 3 |
Amgen
AMGN
|
+$156M |
| 4 |
Cigna
CI
|
+$151M |
| 5 |
Elevance Health
ELV
|
+$148M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.49% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
26
DELISTED
Aerie Pharmaceuticals
AERI
| $102M | 1.27% |
1,884,100
+554,500
| +42% | +$31M |
|
|
27
Tenet Healthcare
THC
$22.3B
| $102M | 1.26% |
+4,189,300
| New | +$83.4M |
|
|
SHPG
28
DELISTED
Shire pic
SHPG
| $97.2M | 1.2% |
650,308
+377,800
| +139% | +$52M |
|
29
Iovance Biotherapeutics
IOVA
$2.04B
| $93.8M | 1.16% |
5,548,326
| – | – |
|
30
Universal Health Services
UHS
$10.1B
| $91.5M | 1.13% |
772,900
+598,100
| +342% | +$71M |
|
|
SEM
31
DELISTED
Select Medical
SEM
| $87.5M | 1.09% |
9,417,715
| – | – |
|
|
IMMU
32
DELISTED
Immunomedics Inc
IMMU
| $83.4M | 1.03% |
5,710,774
-2,750,953
| -33% | -$44.9M |
|
33
Thermo Fisher Scientific
TMO
$216B
| $80.4M | 1% |
389,400
| – | – |
|
|
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
| $80M | 0.99% |
4,900,900
-2,720,500
| -36% | -$43.6M |
|
|
35
Amgen
AMGN
$212B
| $75.9M | 0.94% |
445,310
-851,790
| -66% | -$156M |
|
36
Viatris
VTRS
$20.8B
| $75.5M | 0.94% |
1,834,300
| – | – |
|
37
Acadia Pharmaceuticals
ACAD
$4.46B
| $75.1M | 0.93% |
3,340,700
+2,491,600
| +293% | +$69M |
|
38
Xtant Medical Holdings
XTNT
$59.1M
| $72.6M | 0.9% |
9,207,012
+8,810,813
| +2,224% | +$58M |
|
|
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $70.8M | 0.88% |
1,466,530
-691,200
| -32% | -$38.6M |
|
40
Corvus Pharmaceuticals
CRVS
$1.1B
| $68.8M | 0.85% |
5,967,584
+588,235
| +11% | +$5.56M |
|
41
Illumina
ILMN
$29.3B
| $67.3M | 0.83% |
292,466
-45,232
| -13% | -$10.4M |
|
42
Insmed
INSM
$22.7B
| $65.9M | 0.82% |
2,927,891
+1,431,100
| +96% | +$37.7M |
|
|
VRAY
43
DELISTED
ViewRay, Inc.
VRAY
| $60.8M | 0.75% |
9,458,567
| – | – |
|
|
MGLN
44
DELISTED
Magellan Health Services, Inc.
MGLN
| $60.4M | 0.75% |
563,843
-292,000
| -34% | -$29.3M |
|
45
Johnson & Johnson
JNJ
$645B
| $59.6M | 0.74% |
465,300
| – | – |
|
|
ONC
46
BeOne Medicines Ltd
ONC
$34B
| $59.6M | 0.74% |
354,900
-686,588
| -66% | -$93M |
|
|
BLUE
47
DELISTED
bluebird bio
BLUE
| $59M | 0.73% |
26,680
-2,968
| -10% | -$7.55M |
|
48
Rhythm Pharmaceuticals
RYTM
$7.36B
| $57.7M | 0.72% |
2,901,295
| – | – |
|
49
KALA BIO
KALA
$12M
| $54.6M | 0.68% |
1,381
+430
| +45% | +$16.3M |
|
|
LKFT
50
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $48.6M | 0.6% |
486,990
| – | – |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2018 Portfolio in Review
As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed withdrew a net $9.78B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.
- OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
- OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
- OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
- OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
- OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
- OrbiMed opened 25 new positions and closed 16 in Q1 2018.
- OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.
Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.